Last Updated : December 22, 2022
Details
FilesGeneric Name:
pembrolizumab and lenvatinib
Project Status:
Complete
Therapeutic Area:
Advanced endometrial cancer
Manufacturer:
Merck Canada Inc.
Brand Name:
Keytruda and Lenvima
Project Line:
Reimbursement Review
Project Number:
PC0288-000
Tumour Type:
Gynecology
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Biosimilar:
No
Submission Type:
Initial
Companion Diagnostics:
Yes
Fee Schedule:
Schedule A
Tumour Type:
Genitourinary
Indications:
Keytruda in combination with lenvatinib, is indicated for the treatment of adult
patients with advanced endometrial carcinoma that is not microsatellite
instability high (MSI-H) or mismatch repair deficient (dMMR), who have disease
progression following prior platinum-based systemic therapy, and are not
candidates for curative surgery or radiation.
Date NOC Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
Key Milestones2 | |
|---|---|
| Submission received | March 07, 2022 |
| Submission accepted | March 21, 2022 |
| Review initiated | March 22, 2022 |
| Draft CADTH review report(s) provided to sponsor for comment | May 24, 2022 |
| Deadline for sponsors comments | June 02, 2022 |
| CADTH review report(s) and responses to comments provided to sponsor | June 30, 2022 |
| Expert committee meeting (initial) | July 13, 2022 |
| Draft recommendation issued to sponsor | July 26, 2022 |
| Draft recommendation posted for stakeholder feedback | August 04, 2022 |
| End of feedback period | August 18, 2022 |
| Final recommendation issued to sponsor and drug plans | September 01, 2022 |
| Final recommendation posted | September 20, 2022 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | September 16, 2022 |
| CADTH review report(s) posted | December 06, 2022 |
Files
Last Updated : December 22, 2022